AC Immune SA (IMR.SG)
| Previous close | 2.4120 |
| Open | 2.6040 |
| Bid | 2.3910 x 0 |
| Ask | 2.5410 x 0 |
| Day's range | 2.3720 - 2.6040 |
| 52-week range | 2.1000 - 8.2900 |
| Volume | |
| Avg. volume | 590 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent
Previously reported clinical proof-of-concept data on ACI-12589 showed the PET tracer generating the first live images of alpha-synuclein in the human brainNew grant funding will pave the way for enhanced clinical studiesTotal funding from The Michael J. Fox Foundation for AC Immune’s alpha-synuclein PET tracer program is now up to USD 3.7 million LAUSANNE, Switzerland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision
- GlobeNewswire
AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases
Vaccines can provide safe, long-lasting immunity, and logistical advantages compared to other treatment modalitiesIntegrating its precision medicine approach, AC Immune is advancing three clinical-stage vaccines targeting Tau, Abeta and α-synucleinPrecisely targeted active immunotherapy may enable prevention of pathological pathways before the occurrence of irreversible neuronal damage LAUSANNE, Switzerland, Aug. 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharm
- GlobeNewswire
AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer’s and Parkinson’s Diseases
Webinar to take place on Wednesday, August 24th at 10:00 AM ET / 4:00 PM CETDiscussion to focus on novel therapeutic approaches and the selection of biomarkers and target proteins for active vaccination approaches LAUSANNE, Switzerland, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will host a key opinion leader (KOL) webinar on vaccinations to treat a
